Complement C5-blocking Agent in Refractory Dermatomyositis

J Rheumatol. 2018 Dec;45(12):1710-1711. doi: 10.3899/jrheum.180060. Epub 2018 Sep 15.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Complement C5 / antagonists & inhibitors*
  • Dermatomyositis / complications
  • Dermatomyositis / drug therapy*
  • Female
  • Humans
  • Thrombotic Microangiopathies / complications*
  • Treatment Outcome
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement C5
  • eculizumab